Where will it end?
Federal agents have charged that of Pilot Flying J, the largest truck-stop chain in the country, secretly manipulated purchasing records, routinely cheated trucking companies out of millions of dollars in promised diesel fuel rebates.
Pilot officials and their lawyers say that despite the ongoing investigation, reams of adverse publicity and the abrupt departure of top sales executives, the company has been doing well, with annual revenues topping an estimated $28 billion. Ten of the company's former sales officials await sentencing on fraud charges.
"As a private company, we do not disclose those details, but business is very good," said Rachel Albright, a Pilot spokeswoman. The company has 20,000 employees and is No. 7 on Forbes' list of largest private U.S. companies
5 Best Trucking Stocks To Watch Right Now: Tianrong Internet Products and Services Inc (TIPS)
Tianrong Internet Products and Services, Inc. (TIPS), incorporated on January 29, 1959, is a holding company. The Company is a development-stage company. The Company is engaged in developing and marketing its Website (Phonecalls.com) for commercial exploitation. TIPS is an e-commerce business which is engaged in reselling mobile and other telephony solutions to customers via its Website. The company markets products on behalf of suppliers through search marketing and other e-marketing initiatives, such as virtual mail shots.
The Company�� Website catalogues new and refurbished mobile handsets and landline phones from a range of suppliers, as well as a variety of accessories. Customers can purchase products by clicking directly through to the supplier�� Website and the Company l receives a commission on sales made. Suppliers can upload their product advertisements remotely and independently without any human interaction with the Company.
Advisors' Opinion:- [By Canadian Value]
To quantify the relationship between real gold prices and real yields, we can regress the price of gold from 2006 to 2013 (we used the logarithm of the real price of gold in our model) against the 10-year real yield from the Treasury Inflation-Protected Securities (TIPS) market. (In our view, this regression is appropriate since gold and real yields are co-integrated and there is an economic rationale for believing they should be.) Based on our study, the regression shows that, all else equal, a 100-basis-point (bp) increase in 10-year real yields has historically led to a decline of 26.8% in the inflation-adjusted price of gold. In other words, over the past seven years gold has had a real duration of 26.8 years. (Note that this is solely an empirical duration that describes the way that gold has traded. Since gold has no cash flows, its duration does not need to be constant, and there is nothing magic about the 26.8 number. Just as the correlation between stocks and bonds varies over time depending on changes in macroeconomic variables and investor risk appetite, the real duration of gold may also change in the future.)
5 Best Trucking Stocks To Watch Right Now: Cell Therapeutics Inc (CTIC)
Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.
Pixuvri
As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.
OPAXIO
OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.
Tosedostat
In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.
Brostallicin
As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).
The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.
Advisors' Opinion:- [By Bryan Murphy]
If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.
5 Best Safest Stocks To Buy For 2015: Servotronics Inc.(SVT)
Servotronics, Inc., together with its subsidiaries, engages in the design, manufacture, and marketing of technology and consumer products primarily in the United States. It operates in two segments, Advanced Technology Group (ATG) and Consumer Products Group (CPG). The ATG segment designs, manufactures, and markets various servo-control components that convert an electrical current into a mechanical force or movement, and other related products. Its servo-control components include torque motors, electromagnetic actuators, hydraulic valves, pneumatic valves, and similar devices that are principally sold to commercial aerospace, missile, aircraft, government related, medical, and industrial markets. This segment also produces metallic seals in various cross-sectional configurations that are used to fit between two metal surfaces to produce a secure and leak-proof joint. The ATG segment markets its products primarily through its professional staff to the United States Govern ment, government prime contractors, government subcontractors, commercial manufacturers, and end users. The CPG segment designs, manufactures, and sells various cutlery products, including steak, carving, bread, butcher, and paring knives for household use and for use in restaurants, institutions, and private industry; pocket and other types of knives for use in hunting, fishing, and camping; and machetes, bayonets, and other types of knives for military use. This segment also produces and markets other cutlery items, such as specialty tools, putty knives, linoleum sheet cutters, field knives, and other edged products. The CPG segment markets its products through sales personnel and independent manufacturers? representatives to hardware, supermarket, variety, department, discount, gift, and drug stores, as well as to various branches of the United States Government primarily under the ?Old Hickory? and ?Queen? brand names. Servotronics, Inc. was founded in 1959 and is based in Elma, New York.
Advisors' Opinion:- [By Sofia Horta e Costa]
Severn Trent Plc (SVT) advanced 2.5 percent to 2,070 pence, snapping four days of losses. Borealis Infrastructure Management Inc. and its partners boosted their offer to acquire the water utility to 5.3 billion pounds ($8.2 billion).
5 Best Trucking Stocks To Watch Right Now: Itron Inc.(ITRI)
Itron, Inc. provides products and services for the energy and water markets worldwide. It produces standard electricity, natural gas, and water meters for residential, commercial, industrial, and transmission and distribution customers. The company also offers advanced and smart electronic, gas, and water meters, as well as communication modules; handheld, mobile, and fixed network collection technologies; meter data management software; prepayment systems comprising smart key, keypad, and smart card communication technologies; data warehousing; and knowledge application solutions. It provides communication technologies, which include telephone, radio frequency, global system for mobile communications, power line carrier, and Ethernet devices. In addition, the company offers professional services, including implementation, installation, consulting, system management, and analysis. It markets its products through direct sales, distributors, representative agencies, partners , and meter manufacturer representatives. The company was founded in 1977 and is headquartered in Liberty Lake, Washington.
Advisors' Opinion:- [By Alex Planes]
What: Shares of Itron (NASDAQ: ITRI ) are down nearly 10% after plunging as much as 14% in early trading today after a pre-market earnings report gave investors little cause for optimism in the near term.
- [By John Udovich]
Small cap cloud stock Opower Inc (NYSE: OPWR), a cloud�solutions provider to the utility sector, IPO�� at $19�on Friday to�close at $23 a share, meaning its worth taking a closer look at the stock plus�take a look at the performance of smart meter or smart grid�stocks like�Itron, Inc (NASDAQ: ITRI), Echelon Corporation (NASDAQ: ELON) and EnerNOC, Inc (NASDAQ: ENOC).
- [By John Udovich]
Although small cap smart metering stock Silver Spring Networks Inc (NYSE: SSNI) recently soared on earnings, it also plunged yesterday�after loosing�out on important contract ��meaning it might be time to take a closer look at it along with other smart metering stocks like Itron, Inc (NASDAQ: ITRI) or Echelon Corporation (NASDAQ: ELON) to see if they are smart investments.
5 Best Trucking Stocks To Watch Right Now: Universal Health Realty Income Trust (UHT)
Universal Health Realty Income Trust (Trust) is a real estate investment trust (REIT). It invests in health care and human service related facilities, including acute care hospitals, behavioral healthcare facilities, rehabilitation hospitals, sub-acute facilities, surgery centers, childcare centers and medical office buildings (MOBs). As of February 29, 2012, it had 54 real estate investments or commitments located in 15 states in the United States consisting of seven hospital facilities, including three acute care, one behavioral healthcare, one rehabilitation and two sub-acute; 43 MOBs, and four preschool and childcare centers. In February, 2012, Canyon Healthcare Properties, in which it owned a 95% non-controlling ownership interest, completed the divestiture of the Canyon Springs Medical Plaza. In January, 2012, it purchased the PeaceHealth Medical Clinic, a single-tenant medical office building consisting of approximately 99,000 rentable square feet, located in Bellingham, Washington. During the year ended December 31, 2011, the Company acquired Lake Pointe Medical Arts Building, Forney Medical Plaza, Tuscan Professional Building and Emory at Dunwoody Building, and minority ownership interests held by third-party members in 11 limited liability companies (LLCs). On November 30, 2011 and December 16, 2011, eight LLCs in which it owned various non-controlling, ownership interests, completed the divestitures of medical office buildings and related real property.
As of February 29, 2012, the Company had investments in 54 facilities, located in 15 states and consisting of Southwest Healthcare System, Inland Valley Campus, McAllen Medical Center, Wellington Regional Medical Center, The Bridgeway, Kindred Hospital Chicago Central, Kindred Hospital Corpus Christi, HealthSouth Deaconess Rehabilitation Hospital, Family Doctor�� Medical Office Bldg., Kelsey-Seybold Clinic at Kings Crossing, Professional Bldgs. at Kings Crossing Building A and Building B, Chesterbrook Academy, Southern Cresce! nt Center I, Desert Valley Medical Center, Desert Springs Medical Plaza, and Santa Fe Professional Plaza. As of December 31, 2011, included in its portfolio are seven hospital facilities. During 2011, the leases with respect to these hospital facilities consisted approximately 65% of its revenue. As of December 31, 2011, these leases have fixed terms with an average of 4.4 years remaining and include renewal options ranging from one to five, five-year terms. During 2011, revenues generated from the leases on the Universal Health Services, Inc. (UHS) hospital facilities accounted for approximately 55% of its total revenue. During 2011, it had a total of 41 new or renewed leases related to the medical office buildings.
Advisors' Opinion:- [By Eric Volkman]
Universal Health Realty Income Trust (NYSE: UHT ) is building on the foundation of its shareholder payouts with a modest increase. The company has declared a quarterly dividend of $0.625 per share, to be paid on June 28 to shareholders of record as of June 17. That amount is half a penny higher than the company's previous two disbursements of $0.62 apiece, the most recent of which was handed out in late March.
No comments:
Post a Comment